2019 CYIR Finalized
59 GENETICS OF PULMONARY ARTERIAL HYPERTENSION Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, Trembath RC, Loyd JE. Genetics and genom- ics of pulmonary arterial hypertension. Eur Respir J. 2018 Jan 24;53(1). Summary Based on existing knowledge, around 25–30% of patients diagnosed with idiopathic PAH have an underlying Mendelian genetic cause for their condition. Mutations in BMPR2 remain the most common cause of hereditary (70-80% of families) and idiopathic (10-20%) PAH. In the last year, whole-genome sequencing of large families and patient cohorts have led to the discovery of new genes associated with PAH (TBX4, ATP13A3, GDF2, SOX17, AQP1) and PVOD (EIF2AK4). The role of common genetic variation contributing to the etiology or clinical course of PAH is less well defined and only one GWAS study has been done which detected a locus on CBLN2 with an OR of 1.97. Regarding disease penetrance, studies looking at epigenetic modifiers such as microRNAs, DNA methylation and histone markers have provided evidence of a sophis- ticated network of gene regulation in the pulmonary vas- culature. The document also addresses genetic testing in PAH patients and recommend that this should be offered to PVOD/PCH and selected (hereditary, idiopathic and drug- induced) PAH patients. Genetic education and counselling should be performed prior to genetic testing for PAH to address the complex issues of incomplete penetrance, sur- veillance, reproductive questions and psychosocial issues. Comments 1. BMPR2 mutations remain the most common cause of heredi- tary PAH. 2. Prevalence and penetrance of newly discovered gene muta- tions remains to be determined. 3. PVOD/PCH patients should be screened for mutations in EIF2AK4. 4. Genetic testing should be considered in patients with family history of PAH and PVOD/PCH. CHRONIC THROMBOEMBOLIC PULMONARY VASCULAR DISEASE Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018. Summary Chronic thromboembolic disease (CTED) is a new entity characterized by similar symptoms and perfusion defects as chronic thromboembolic pulmonary hypertension (CTEPH) but without PH at rest. At present, there is no evidence that CTED evolves to CTEPH. Cardiopulmonary exercise tests and echocardiographic evaluations are recommended to exclude patients with other causes for dyspnea (e.g. obesity, deconditioning). Selected patients with CTED may benefit from pulmonary endarterectomy (PEA), but major perioperative complications can occur in 40% of patients. Regarding CTEPH, the new treatment guidelines still recommend anticoagulation and PEA as the treatment of choice. For those deemed inoperable, the recommendation is to use medical therapy (Riociguat) and consider balloon angioplasty (BPA). The place of PH-targeted medical therapy and BPA relative to surgery is dependent on the anatomical distribution of disease and is not fully defined. Using medical therapy as a “bridge to PEA” is more controversial, and is felt to delay timely surgical referral and, therefore, definitive treatment Patients with symptomatic PH following PEA should receive medical therapy and be considered for BPA or repeat PEA if indicated. Combining endarterectomy with BPA either as a hybrid or stepwise approach is being studied at select centers of excellence. Comments 1. CTED is a new clinical entity in which PH is absent but perfu- sion defects are present. 2. PEA remains the treatment of choice for CTEPH. 3. BPA should be considered in selected cases of inoperable CTEPH. 4. The role for medical therapy as a bridge to PEA remains to be established. DRUG AND TOXIN-INDUCED PULMONARY HYPERTENSION Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V*, Kawut SM*. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. Summary The classification of PAH associated with drugs and toxins was revised to include drugs with Definite (i.e. data based on outbreaks, epidemiological case–control studies or large multicenter series) and Possible (i.e. multiple case series or cases with drugs with similar mechanisms of action) asso- ciation. Methamphetamine is now considered a definite cause of PAH (METH-PAH) based on a large series of 90 cases seen at Stanford University over 10 years. Compared to IPAH, METH-PAH patients are less likely to be female, have more severe hemodynamic compromise at diagnosis and worse outcomes. Given reports of PAH associated with drugs routinely used in clinical practice (e.g. tyrosine kinase inhibitors, antiretrovirals, interferons), it is imperative that pharmacovigilance efforts be undertaken to take action and avoid future PAH epidemics. UPDATE ON PULMONARY VASCULAR DISEASES
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw